About: BACKGROUND: Passive immunotherapy approaches are being developed to prevent and treat a variety of human medical conditions. Here we report the first use of a fully-human polyclonal IgG immunoglobulin (SAB-301) produced from hyperimmune plasma of transchromosomic (Tc) cattle immunized with a Middle East Respiratory Syndrome (MERS) coronavirus vaccine. METHODS: We conducted a double-blind, placebo-controlled, single dose escalation study in six cohorts of 3–10 participants who were randomly assigned by a computer-generated table to receive 1, 2.5, 5, 10, 20, or 50 mg/kg of SAB-301 or placebo on Day 0, and were followed by clinical, laboratory, and pharmacokinetic assessments on days 1, 3, 7, 21, 42 and 90. The primary outcome was safety whereas pharmacokinetic profile, MERS virus neutralization assay over time (pharmacodynamics), and immunogenicity were secondary outcomes. The analysis was performed on the intention to treat population. ClinicalTrials.gov Identifier: NCT02788188. FINDINGS: We randomized 38 participants (28 to SAB-301 and 10 to placebo). Ninety-seven adverse event (AEs) were reported: 64 AEs occurred in 23 of 28 participants (82%) receiving SAB-301 (mean 2.3 AEs per participant), and 33 AEs occurred in 10 of 10 participants (100%) receiving placebo (mean 3.3 AEs per participant). The most common AEs were headache, albuminuria, elevated creatine kinase, and common cold, and occurred in similar proportions as placebo. Single dose pharmacokinetics (PK) demonstrated relatively linear and dose-proportional increases in maximal concentration and area-under-the-concentration-time curve (AUC(0–24)), and the PK strongly correlated with the microneutralization assay (R(2)=0.845, p<0.001). The AUC in the 50 mg/kg dose (27498.18 μg*days/mL) is comparable to the AUC that was associated with protection in a preclinical model. The average terminal elimination half-life (t(1/2)) was ~ 28 days. INTERPRETATION: Single infusions of SAB-301 up to 50 mg/kg appear to be safe and well-tolerated in healthy participants. Tc cattle derived human immunoglobulin offers a new platform technology to produce fully-human polyclonal IgG immunoglobulin for other medical conditions. FUNDING: National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States.   Goto Sponge  NotDistinct  Permalink

An Entity of Type : fabio:Abstract, within Data Space : wasabi.inria.fr associated with source document(s)

AttributesValues
type
value
  • BACKGROUND: Passive immunotherapy approaches are being developed to prevent and treat a variety of human medical conditions. Here we report the first use of a fully-human polyclonal IgG immunoglobulin (SAB-301) produced from hyperimmune plasma of transchromosomic (Tc) cattle immunized with a Middle East Respiratory Syndrome (MERS) coronavirus vaccine. METHODS: We conducted a double-blind, placebo-controlled, single dose escalation study in six cohorts of 3–10 participants who were randomly assigned by a computer-generated table to receive 1, 2.5, 5, 10, 20, or 50 mg/kg of SAB-301 or placebo on Day 0, and were followed by clinical, laboratory, and pharmacokinetic assessments on days 1, 3, 7, 21, 42 and 90. The primary outcome was safety whereas pharmacokinetic profile, MERS virus neutralization assay over time (pharmacodynamics), and immunogenicity were secondary outcomes. The analysis was performed on the intention to treat population. ClinicalTrials.gov Identifier: NCT02788188. FINDINGS: We randomized 38 participants (28 to SAB-301 and 10 to placebo). Ninety-seven adverse event (AEs) were reported: 64 AEs occurred in 23 of 28 participants (82%) receiving SAB-301 (mean 2.3 AEs per participant), and 33 AEs occurred in 10 of 10 participants (100%) receiving placebo (mean 3.3 AEs per participant). The most common AEs were headache, albuminuria, elevated creatine kinase, and common cold, and occurred in similar proportions as placebo. Single dose pharmacokinetics (PK) demonstrated relatively linear and dose-proportional increases in maximal concentration and area-under-the-concentration-time curve (AUC(0–24)), and the PK strongly correlated with the microneutralization assay (R(2)=0.845, p<0.001). The AUC in the 50 mg/kg dose (27498.18 μg*days/mL) is comparable to the AUC that was associated with protection in a preclinical model. The average terminal elimination half-life (t(1/2)) was ~ 28 days. INTERPRETATION: Single infusions of SAB-301 up to 50 mg/kg appear to be safe and well-tolerated in healthy participants. Tc cattle derived human immunoglobulin offers a new platform technology to produce fully-human polyclonal IgG immunoglobulin for other medical conditions. FUNDING: National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States.
subject
  • Virology
  • Immune system
  • Bat virome
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software